In the hippocampus of AD animals, reduced levels of Aβ plaques (sAPPβ, Aβ42, and Aβ40) and attenuated JNK signaling were achieved by C66 treatment [50]. This evidence concerns the gene MAPK8 and Alzheimer disease.